Coronavirus: Hospitals in Paris are hopeful of finding treatment for severe cases
A state-of-the-art therapeutic trial with a molecule which combats the inflammatory reaction, tocilizumab (marketed by Roche under the name Actemra), shows encouraging results. The hospital group did not wish to reveal the precise results, until they have been approved by the reading committee of the scientific journal which could publish them.
According to Bruno Lina in today's "C dans l'air" show the results are very interesting.
The demonstration was carried out as part of the Corimuno therapeutic trial, which brings together more than 420 Covid-19 patients and has several "arms" (sarilumab, serum from cured patients, etc.). For 14 days, 129 patients were included in the tocilizumab arm, of which 65 received this molecule marketed by the Roche laboratory under the name Actemra, and 64 were treated in the usual way - oxygen, antibiotics, anticoagulants. All were already on oxygen, a sign of a serious form of the disease. The objective, which was to reduce the risk of going into intensive care and increase the chances of survival, was achieved. But we do not know in what proportions.
822 € the dose ??This drug, whose injection costs 822 euros, does not present any particular difficulty of supply, also points to the AP-HP
The article is here: https://www.lesechos.fr/economie-france ... es-1198509